Toxoplasmosis in Spain, analysis of hospitalizations during the period 1997-2018
e202112194
Keywords:
Toxoplasmosis, Toxoplasma gondii infectionon, Hospital admissionsAbstract
Background: Toxoplasmosis is a systemic infectious disease. Infection is acquired by ingestion of Toxoplasma gondii cysts or by vertical transmission mother-to-child during pregnancy (congenital toxoplasmosis). In Spain, the prevalence shows wide variability depending on the region and the study. The incidence in other European countries evidences a decline in recent years. The aim of this study was to characterize the presence and the epidemiological patterns of the disease in the Spanish population with information obtained of hospitalized cases with a diagnosis of toxoplasmosis at discharge.
Methods: The interactive platform of the Specialized Registry (RAE-MBD) of the Ministry of Health was used to obtain data on hospital discharges with “toxoplasmosis” diagnosis. Frequencies and rates of hospital discharges were calculated according to sex, age groups, region and diagnosis at discharge. Sequence graphs were generated to analysed the temporal evolution of the number of hospitalizations. The trends and slopes of the RHs were analyzed using “joinpoint” regression models, estimating the mean annual percentage change (PCAM) in the RHs and its 95% confidence interval.
Results: There were 13,704 cases with toxoplasmosis diagnosis at discharge, (58%) were men. The highest hospitalization rate (RH) was in the 15-44-year-old men group (5,804 discharges and HT=2.52). During the period studied a decrease in the number of discharges was observed, it was progressive and affected all the autonomous regions, being more pronounced in men (81.9% vs 63.9%).
Conclusions: The number of hospitalizations in Spain decreased substantially during the studied period (1997-2018), similar to other European studies reported. The decrease was progressive and mainly affected men between 15-44 years.
Downloads
References
Heymann DL (2015). Control of communicable diseases manual. An official report of the American Public Health Association. 20 Ed. Apha Press. (pp. 614-617).
Protocolo de la Red de Vigilancia Epidemiológica de Toxoplasmosis Congénita. Protocolos de la Red Nacional de Vigilancia Epidemiológica. Instituto de Salud Carlos III. Junio, 2015; 604-612. Disponible en: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/PROTOCOLOS/Protocolo%20de%20Vigilancia%20de%20Toxoplasmosis%20Cong%C3%A9nita.pdf [citado mayo de 2021].
Nogareda F, Le Strat Y, Villena I, De Valk H, Goulet V. Incidence and prevalence of Toxoplasma gondii infection in women in France, 1980-2020: model-based estimation. Epidemiol Infect. 2014 Aug;142(8):1661-70. doi: 10.1017/S0950268813002756
Flegr J, Prandota J, Sovičková M, Israili ZH. Toxoplasmosis--a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. PLoS One. 2014 Mar 24;9(3):e90203. doi: 10.1371/journal.pone.0090203.
Said B, Halsby KD, O’Connor CM, Francis J, Hewitt K, Verlander NQ et al. Risk factors for acute toxoplasmosis in England and Wales. Epidemiol Infect. 2017 Jan;145(1):23-29. doi: 10.1017/S0950268816002235.
Furtado JM, Smith JR, Belfort R Jr, Gattey D, Winthrop KL. Toxoplasmosis: a global threat. J Glob Infect Dis. 2011 Jul;3(3):281-4. doi: 10.4103/0974-777X.83536.
Aguirre AA, Longcore T, Barbieri M, Dabritz H, Hill D, Klein PN et al. The One Health Approach to Toxoplasmosis: Epidemiology, Control, and Prevention Strategies. Ecohealth. 2019 Jun;16(2):378-390. doi: 10.1007/s10393-019-01405-7.
Rostami A, Riahi SM, Gamble HR, Fakhri Y, Nourollahpour Shiadeh M et al. Global prevalence of latent toxoplasmosis in pregnant women: a systematic review and meta-analysis. Clin Microbiol Infect. 2020 Jun;26(6):673-683. doi: 10.1016/j.cmi.2020.01.008.
Ministerio de Sanidad, Consumo y Bienestar Social. (2019) Registro de Atención Sanitaria Especializada RAE – CMBD. Manual de definiciones y glosario de términos. Portal estadístico. https://pestadistico.inteligenciadegestion.mscbs.es/publicoSNS/S/rae-cmbd. Acceso en noviembre de 2020 y abril de 2021.
Joinpoint Trend Analysis Software [Internet]. Disponible en: https://surveillance.cancer.gov/joinpoint/ [citado abril de 2021].
Said B, Halsby KD, O’Connor CM, Francis J, Hewitt K, Verlander NQ et al. Risk factors for acute toxoplasmosis in England and Wales. Epidemiol Infect. 2017 Jan;145(1):23-29. doi: 10.1017/S0950268816002235
Agencia Española de Seguridad Alimentaria. Aplicación de radiaciones ionizantes a los alimentos. N Ref: AESA-2003-004. Doc del Comité Científico, 22 septiembre 2004.
Opsteegh M, Kortbeek TM, Havelaar AH, van der Giessen JW. Intervention strategies to reduce human Toxoplasma gondii disease burden. Clin Infect Dis. 2015;60(1):101-107. https://doi.org/10.1093/cid/ciu721
Le LT, Spudich SS. HIV HIV-Associated Neurologic Disorders and Central Nervous System Opportunistic Infections in HIV. Semin Neurol, 2016;36(4):373-81. doi: 10.1055/s-0036-1585454
European Centre for Disease Prevention and Control. Congenital toxoplasmosis. In: ECDC. Annual epidemiological report for 2017. Stockholm: ECDC; 2019.
Menchi-Elanzi M, Mayoral AM, Morales J, Pinargote-Celorio H, González-Alcaide G, Ramos-Rincón JM. Toxoplasma gondii infection in hospitalized people living with HIV in Spain, 1997 to 2015. Parasitol Res. 2021 Feb;120(2):755-761. doi: 10.1007/s00436-020-07007-5
Soriano V, Ramos JM, Barreiro P, Fernandez-Montero JV. 5AIDS Clinical Research in Spain-Large HIV Population, Geniality of Doctors, and Missing Opportunities. Viruses, 2018;10(6):293.
Martin-Iguacel R, Ahlström MG, Touma M, Engsig FN, Stærke NB, Stærkind M et al. Incidence, presentation and outcome of toxoplasmosis in HIV infected in the combination antiretroviral therapy era. J Infect. Secur 2017;75(3):263-273.19.
Rajapakse S, Weeratunga P, Rodrigo C, de Silva NL, Fernando SD. Prophylaxis of human toxoplasmosis: a systematic review. Pathog Glob Health. 2017 Oct;111(7):333-342. doi: 10.1080/20477724.2017.1370528
Robert-Gangneux F, Meroni V, Dupont D, Botterel F, Aguado Garcia JM, Brenier-Pinchart MP et al. Toxoplasmosis in Transplant Recipients, Europe, 2010–2014. Emerg Infect Dis. 2018; 24: 1497–1504. doi: 10.3201/eid2408.180045
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Rosa Mª Estévez Reboredo, Isabel de Fuentes Corripio, Rocío Carmona, Rosa Cano Portero
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
